» Articles » PMID: 38001898

SARS-CoV-2 Affects Thyroid and Adrenal Glands: An F-FDG PET/CT Study

Abstract

Background: Since most endocrine glands express ACE-2 receptors and can be infected by SARS-CoV-2 virus, this retrospective multicentre observational study aims to assess the metabolic activity of thyroid and adrenal glands of COVID-19 patients by F-FDG PET/CT.

Methods: We retrospectively evaluated the F-FDG PET/CT scans of COVID-19 patients admitted by three different centres, either in a low-intensity department or in the intensive care unit (ICU). A visual assessment and a semi-quantitative evaluation of areas of interest in thyroid and adrenal glands were performed by recording SUVmax and SUVmean. The F-FDG PET/CT uptake in COVID-19 patients was compared with those observed in normal age-matched controls.

Results: Between March 2020 and March 2022, 33 patients from three different centres (twenty-eight patients in a low-intensity department and five patients in ICU), were studied by F-FDG PET/CT during active illness. Seven of them were also studied after clinical remission (3-6 months after disease onset). Thirty-six normal subjects were used as age-matched controls. In the thyroid gland, no statistically significant differences were observed between control subjects and COVID-19 patients at diagnosis. However, at the follow-up PET/CT study, we found a statistically higher SUVmax and SUVmean ( = 0.009 and = 0.004, respectively) in the thyroid of COVID-19 patients. In adrenal glands, we observed lower SUVmax and SUVmean in COVID-19 patients at baseline compared to control subjects ( < 0.0001) and this finding did not normalize after clinical recovery ( = 0.0018 for SUVmax and = 0.002 for SUV mean).

Conclusions: In our series, we observed persistent low F-FDG uptake in adrenal glands of patients at diagnosis of COVID-19 and after recovery, suggesting a chronic hypofunction. By contrast, thyroid uptake was comparable to normal subjects at disease onset, but after recovery, a subgroup of patients showed an increased metabolism, thus possibly suggesting the onset of an inflammatory thyroiditis. Our results should alert clinicians to investigate the pituitary-adrenal axis and thyroid functionality at the time of infection and to monitor them after recovery.

Citing Articles

Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology.

Ewing A, Salamon S, Pretorius E, Joffe D, Fox G, Bilodeau S Med Rev (2021). 2025; 5(1):66-75.

PMID: 39974559 PMC: 11834749. DOI: 10.1515/mr-2024-0030.


Long Covid: Hormone Imbalances and/or Rather Complex Immune Dysregulations?.

Koch C J Endocr Soc. 2024; 8(5):bvae043.

PMID: 38515584 PMC: 10957124. DOI: 10.1210/jendso/bvae043.


Emerging Trends in Complications Associated with SARS-CoV-2 Infection.

Rosca E, Cornea A, Simu M Biomedicines. 2024; 12(1).

PMID: 38275366 PMC: 10813045. DOI: 10.3390/biomedicines12010004.

References
1.
Ahn S, Hwang S, Jung S, Lee S, Park Y, Yun M . The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome. Medicine (Baltimore). 2017; 96(34):e7901. PMC: 5572033. DOI: 10.1097/MD.0000000000007901. View

2.
Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P . Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. 2021; 48(10):3187-3197. PMC: 7937050. DOI: 10.1007/s00259-021-05294-3. View

3.
Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

4.
Kumar R, Guruparan T, Siddiqi S, Sheth R, Jacyna M, Naghibi M . A case of adrenal infarction in a patient with COVID 19 infection. BJR Case Rep. 2020; 6(3):20200075. PMC: 7465735. DOI: 10.1259/bjrcr.20200075. View

5.
Jamar F, Buscombe J, Chiti A, Christian P, Delbeke D, Donohoe K . EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013; 54(4):647-58. DOI: 10.2967/jnumed.112.112524. View